Alpelisib

What is Alpelisib?

Alpelisib is a prescription medication used in the treatment of certain types of advanced breast cancer. It belongs to a class of drugs known as kinase inhibitors, specifically targeting the phosphoinositide 3-kinase (PI3K) pathway. This oral medication offers a targeted approach for patients whose tumors have a specific genetic alteration.

Approved for use in adults, Alpelisib is specifically indicated for those with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer that has progressed after endocrine-based therapy. Crucially, its use is restricted to patients whose tumors have a confirmed PIK3CA mutation, a key genetic marker that predicts responsiveness to this drug. It is typically administered in combination with fulvestrant.

How Does it Work?

The mechanism of action of Alpelisib revolves around its ability to inhibit the PI3K pathway. The PI3K pathway is a crucial signaling network within cells that plays a vital role in cell growth, proliferation, survival, and metabolism. In many cancers, this pathway can become overactive due to mutations in genes like PIK3CA, leading to uncontrolled cell growth and tumor progression.

As a selective PI3K inhibitor, Alpelisib works by blocking the activity of the mutated PI3K enzyme. By disrupting this abnormal signaling cascade, it helps to slow down or stop the growth of cancer cells. This targeted approach specifically addresses the underlying genetic driver of the cancer, making it an effective treatment option for patients with PIK3CA-mutated tumors.

Medical Uses

The primary medical use of Alpelisib is in the treatment of advanced or metastatic breast cancer. Specifically, it is indicated for:

• Adults with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
• Patients whose disease has progressed after at least one endocrine-based regimen in the metastatic setting.
• Individuals whose tumors have a confirmed PIK3CA mutation, which is essential before starting treatment.

Alpelisib is almost always prescribed in combination with fulvestrant, an estrogen receptor antagonist, to enhance its efficacy. This combination therapy provides a synergistic effect, targeting the cancer through multiple pathways.

Dosage

The recommended dosage of Alpelisib is 300 mg (two 150 mg tablets) taken orally once daily with food. Patients should swallow the tablets whole and not chew, crush, or split them. If a dose is missed, it should be taken as soon as possible on the same day, but not more than 9 hours after the usual scheduled time. If more than 9 hours have passed, the missed dose should be skipped.

Dose adjustments may be necessary based on individual patient tolerance and the occurrence of side effects. Your healthcare provider will monitor you closely and may temporarily interrupt treatment, reduce the dose, or permanently discontinue Alpelisib if severe side effects occur. Adherence to the prescribed dosage and instructions is vital.

Side Effects

Like all medications, Alpelisib can cause side effects. Patients should report any concerning symptoms to their healthcare provider. Common side effects often include:

• Hyperglycemia (high blood sugar): A very common and potentially serious side effect, requiring careful monitoring and management.
• Rash (including severe skin reactions)
• Diarrhea, nausea, vomiting
• Fatigue, decreased appetite
• Changes in blood tests (e.g., elevated liver enzymes)
• Stomatitis (mouth sores)

More serious, though less common, side effects can include severe skin reactions (like Stevens-Johnson syndrome), pneumonitis (inflammation of the lungs), and colitis (inflammation of the colon). Patients should seek immediate medical attention if they experience severe rash, blistering, fever, difficulty breathing, or severe abdominal pain. Regular monitoring is essential throughout treatment.

Drug Interactions

Alpelisib can interact with other medications, potentially altering its effectiveness or increasing the risk of side effects. Always inform your healthcare provider about all prescription, over-the-counter, and herbal supplements you are taking.

• CYP3A4 Inhibitors and Inducers: Strong CYP3A4 inhibitors (e.g., clarithromycin) can increase Alpelisib levels, while strong CYP3A4 inducers (e.g., rifampin) can decrease them, affecting efficacy or safety.
• Drugs Affecting Glucose Metabolism: Concomitant use with other medications that affect blood glucose levels (e.g., corticosteroids, certain diuretics) requires careful monitoring due to Alpelisib's risk of hyperglycemia.
• P-glycoprotein (P-gp) Substrates: Alpelisib is a P-gp inhibitor, which can increase the concentration of other drugs that are P-gp substrates (e.g., digoxin), potentially increasing their toxicity.

Always consult with your doctor or pharmacist before starting any new medications while on Alpelisib treatment.

FAQ

Q: Who is Alpelisib for?

Alpelisib is for adult patients with HR+, HER2- advanced or metastatic breast cancer that has progressed after prior endocrine therapy, specifically if their tumor has a PIK3CA mutation.

Q: How is Alpelisib taken?

It is taken orally, 300 mg once daily, with food. Swallow tablets whole.

Q: What are the most common side effects?

The most common side effects include high blood sugar (hyperglycemia), rash, diarrhea, nausea, fatigue, and decreased appetite.

Q: Can Alpelisib be used during pregnancy?

No, Alpelisib can harm an unborn baby. Women and men with partners of childbearing potential should use effective contraception during and after treatment.

Q: How long do I take Alpelisib?

Treatment continues as long as the patient benefits and tolerates the medication. Your doctor will determine the duration.

Products containing Alpelisib are available through trusted online pharmacies. You can browse Alpelisib-based medications at ShipperVIP or Medicenter.

Summary

Alpelisib represents a crucial advance in the treatment of specific types of advanced breast cancer. As a targeted therapy, it specifically addresses tumors with a PIK3CA mutation, offering a personalized approach for patients with HR+, HER2- metastatic breast cancer that has progressed after endocrine therapy. Its mechanism as a PI3K inhibitor helps to control cancer cell growth, improving outcomes for eligible patients. While effective, it's associated with potential side effects, particularly hyperglycemia, which require careful monitoring and management. Close collaboration with healthcare professionals, adherence to dosage, and awareness of drug interactions are essential for maximizing benefits and minimizing risks, reinforcing its role as a vital tool in modern oncology.